Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Schizoaffective Disorder
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
A trial to compare if one 15 mg under the tongue tablet is equal to three 5 mg under the tongue tablets of Org 5222 (asenapine) in subjects with schizophrenia or schizoaffective disorder delivered.
- Trial name
- NCT01101464
- Testing
- Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg
- Volunteers
- 8 people
- Sponsor
- Organon and Co
Schizophrenia
A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
The purpose of the study was an Open Label Extension to the recurrence prevention study to evaluate long-term safety and tolerability of paliperidone ER in subjects with schizophrenia.
- Trial name
- NCT00645307
- Testing
- Extended Release OROS® Paliperidone
- Volunteers
- 235 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
SPECT Study With SB-773812 In Schizophrenic Patients
This study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic D2 receptor occupancy (D2 RO ) and serotoninergic 5HT2A receptor occupancy at stable plasma concentration…
- Trial name
- NCT00269035
- Testing
- SB773812, Risperidone
- Where
- 6 sites in Spain
- Volunteers
- 95 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Psychosis
Physical Activity Level in Psychosis Patients
The aim of this study was to examine the effect of physical activity level on social participation, functioning and quality of life in patients with psychosis.
- Trial name
- NCT06408740
- Where
- Turkey (Türkiye)
- Volunteers
- 157 people
- Sponsor
- Bandırma Onyedi Eylül University
Schizophrenia
Carnosine and Cognitive Training in Schizophrenia
This is a double-blind placebo-controlled trial to evaluate the effects of the combination of a cognition enhancing drug, i.e carnosine, with cognitive training in patients with schizophrenia.
- Trial name
- CACTIS (NCT02686697)
- Testing
- L-Carnosine, Cognitive Training
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Abraham Reichenberg
Schizophrenia
Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial
Objective: to evaluate the effectiveness of specialised and sustained intervention with or without parent groups during the initial phase of schizophrenia or related disorders on relapse prevention Methods: A three conditions…
- Trial name
- NCT01936220
- Testing
- Continuity of specialized care, Parent groups combined with Continuity of Specialized care, Discontinuity of care, non specialised care
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Schizophrenia
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)
This PPG entitled "A Study on Psychopathological Progress of Early Schizophrenia-like Disorder (SOPRES)" is designed to study the "Progress of Psychopathology" of pre-psychotic state of schizophrenia (SCH) using a prospective…
- Trial name
- NCT00173069
- Volunteers
- 324 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
- Trial name
- NCT06961968
- Testing
- iloperidone
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Chinese Han People
Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Several chromosomal loci obtained from genetic linkage studies have been reported of relating to schizophrenia. These areas include of 1q32-41, 6p24-21, 8p22-21, 15q13-14, and 22q11-12.
- Trial name
- NCT00155818
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Psychotic Disorders, Schizophrenia
Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study
Recent research has suggested that mindfulness-based interventions for psychosis may be effective in reducing the negative symptoms of schizophrenia (e.g., social withdrawal, lack of motivation) and the distress associated with…
- Trial name
- NCT02342210
- Testing
- Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
- Volunteers
- 21 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Psychotic Disorder, Cognitive Function 1, Social
Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland
33 individuals with a psychotic disorder were given 22-24 sessions weekly or twice weekly of Social Cognition and Interaction Training (SCIT) and evaluated at the baseline and after the intervention.
- Trial name
- NCT02399020
- Testing
- Social Cognition and Interaction Training
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Helsinki University Central Hospital
Schizophrenia
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, fixed-dosed phase II clinical study to evaluate the efficacy and safety of LY03020 in chinese acutely psychotic adult subjects with…
- Trial name
- NCT07396870
- Testing
- LY03020
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Luye Pharma Group Ltd.
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Randomized Controlled Trial
Exploring the Effect of Baduanjin on the Metabolic Parameters and Body Mass Index of People With Schizophrenia
Baduanjin seems to be effective for improving body mass index and fasting sugar in male individuals with schizophrenia. Aim This study was to explore the effect of Baduanjin on the five metabolic parameters and body mass index in…
- Trial name
- NCT04069988
- Testing
- Baduanjin program
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
Research of Anatomo-functional Biomarkers in Schizophrenia
To objectify UR biomarkers, we propose a longitudinal follow-up of resistant patients with schizophrenia, starting before the onset of clozapine and including a multimodal brain imaging assessment (T1 and T2 weighted sequences…
- Trial name
- CLOZAREST (NCT03996122)
- Testing
- fMRI
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Caen
Schizophrenia, Bipolar 1 Disorder
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e.
- Trial name
- NCT03386851
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Affective Disorders, Psychotic Disorder
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia
This study applied a randomized parallel case-controlled design. The study purpose was to evaluate the effects of progressive muscle relaxation on anxiety, psychiatric symptoms and quality of life among patients with chronic…
- Trial name
- NCT03667729
- Testing
- progressive muscle relaxation
- Volunteers
- 75 people
- Sponsor
- Taipei Medical University
Schizophrenia, Schizoaffective Disorder
Oxytocin and CBSST for People With Schizophrenia
A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social…
- Trial name
- NCT01752712
- Testing
- CBSST + Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Psychotic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with…
- Trial name
- NCT00249119
- Testing
- risperidone
- Volunteers
- 1,579 people
- Sponsor
- Janssen, LP
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.